Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results -- Update
Novo Nordisk said CagriSema appeared to have a safe and well-tolerated profile in the latest trial. The most common adverse events were gastrointestinal, and the vast majority were mild to moderate and diminished over time. Novo Nordisk expects to file for the first regulatory approval of CagriSema in the first quarter of 2026.
New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.
Most HHS workers were emailed an offer to leave their job for as much as $25,000 as part of President Trump’s government cuts ...
It seems like no matter what I do, I can't lose weight. Most of my family members struggle with their weight too. Do our ...
It's not too often that pharmaceutical drugs become household names, but that's happening with medicines in the weight loss market. Brands such as Wegovy and Zepbound -- the leading anti-obesity ...
Some commercially insured patients stand to save $150 per month on Wegovy, a popular obesity medication. Patients on Medicare ...
Stanford Medicine researchers have identified a naturally occurring molecule that mimics the appetite-suppressing effects of ...
The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...
Howl-lelujah! Dogs and humans are fatter than ever — it’s no surprise that overweight people tend to have overweight dogs.
Avocados, fatty fish, salad dressing, nuts and yogurt are high-fat foods that can support weight loss. Fat provides energy ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback